---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Cost-effectiveness evidence"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Cost-effectiveness evidence. Topics: Company estimate of the addressable population; Company statements on market opportunity and site of care, June 2026; Company payer research, August 2026; Company market access leadership with gene therapy experience; 11 further topics. 16 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics/cost-effectiveness"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary

No economic model, cost-effectiveness analysis, budget impact analysis, or health technology assessment of lonimecgene renparvovec (TSHA-102) was identified, and Taysha Gene Therapies has announced no price. Taysha estimates an addressable population of 15,000 to 20,000 patients with typical Rett syndrome caused by a pathogenic or likely pathogenic MECP2 mutation in the United States, the European Union, and the United Kingdom. In its second quarter 2026 results announcement, the company reported completed payer research in which TSHA-102 was viewed as a high-value therapy, with durable functional benefit as the key value determinant; its annual report states that the reimbursement structure of other companies' approved gene therapies could affect the anticipated reimbursement structure of its own products.

Trofinetide (DAYBUE) was approved by the FDA in March 2023 for the treatment of Rett syndrome. Acadia stated a list price of $21.10 per mL, or an estimated average net realized cost to payers of about $375,000 per year. Net product sales of DAYBUE were $177.2 million in 2023, $348.4 million in 2024, and $391.4 million in 2025. In a real-world analysis, 766 of 2,950 eligible individuals (26.0%) initiated trofinetide in the early post-approval period.

Canada's Drug Agency (CDA-AMC) appraised the sponsor's cost-effectiveness and budget impact analyses for trofinetide, and amounts below are those reported in that review. The sponsor's Markov cost-utility model, with 4 health states defined by Rett Syndrome Behaviour Questionnaire (RSBQ) score plus death and a lifetime horizon of 79.1 years, produced an incremental cost-effectiveness ratio of $5,864,321 per quality-adjusted life-year (QALY) gained (incremental costs $3,386,675; incremental QALYs 0.578), and a price reduction of more than 98% would be required to meet a threshold of $100,000 per QALY gained. Health state utilities, from a discrete choice experiment commissioned to develop utility-based scoring weights for the RSBQ, ranged from 0.6409 (mild to moderate) to 0.2160 (very severe). The sponsor's budget impact analysis, from the perspective of the pan-Canadian drug plans, assumed 95, 21, and 22 patients would start publicly reimbursed trofinetide in years 1, 2, and 3; the CDA-AMC reanalysis estimated a 3-year incremental budgetary cost of $166,461,725, with scenario analyses up to $333 million, and CDA-AMC recommended that trofinetide not be reimbursed by public drug plans. A systematic literature review screened 221 unique citations for pharmacoeconomic models and found no eligible publication.

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm); [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm); [Managed Healthcare Executive (2023)](https://www.managedhealthcareexecutive.com/view/fda-approves-first-treatment-for-rett-syndrome); [Acadia Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm); [Rashid et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13264036/); [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1); [CDA-AMC trofinetide reimbursement recommendation (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829/2636?inline=1); [May et al. (2024b)](https://acadia.com/en-us/pdf/healthcare-professionals/scientific-publications/congress-materials/2024_EAN_May_HTA_SLR_Pos.pdf)

<a id="topic-4.1-2"></a>

### Published economic model of TSHA-102

No evidence found.

<a id="topic-4.1-3"></a>

### Cost-effectiveness or budget impact analysis of TSHA-102

No evidence found.

<a id="topic-4.1-4"></a>

### Health technology assessment of TSHA-102

No evidence found.

<a id="topic-4.1-5"></a>

### Announced price or pricing guidance for TSHA-102

No evidence found.

<a id="topic-4.1-6"></a>

### Company estimate of the addressable population

> “The estimated addressable patient population with typical Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is between 15,000 and 20,000 patients in the United States, European Union and United Kingdom.”
> “Incidence and prevalence estimates are frequently based on information and assumptions that are not exact and may not be appropriate, and the methodology is forward-looking and speculative.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

> “Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="topic-4.1-7"></a>

### Company statements on market opportunity and site of care, June 2026

> “Commercial launch and uptake of DAYBUE highlights market demand”
> “TSHA-102 delivered intrathecally, a minimally invasive procedure with outpatient potential, enabling broad, scalable access”

Source: [Taysha Gene Therapies June 2026 program update presentation (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex992.htm)

<a id="topic-4.1-8"></a>

### Company payer research, August 2026

> “Completed payer research to inform market access planning, which demonstrated strong support for TSHA-102’s significant value proposition and reimbursement potential, including:”
> “TSHA-102 was viewed as a high-value therapy due to its transformative disease-modifying potential in a population with high unmet need, combined with the convenience of a one-time IT administration that can be performed in an outpatient setting”
> “Payers emphasized the importance of demonstrating clinically meaningful, durable functional gains and improvements that translate into real-world benefits”
> “Strong efficacy, safety and durability are expected to drive coverage and reimbursement, with durable functional benefits serving as the key value determinant in this high unmet need setting”

Source: [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

<a id="topic-4.1-9"></a>

### Company market access leadership with gene therapy experience

> “Further strengthened commercial leadership team with the appointment of Brad Martin as Senior Vice President, Market Access and Value in February 2026.”
> “At AveXis, he played a crucial role in securing market access for the blockbuster gene therapy Zolgensma for the treatment of spinal muscular atrophy.”

Source: [Taysha Gene Therapies full-year 2025 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/d46409dex991.htm)

<a id="topic-4.1-10"></a>

### Company statements on reimbursement precedent of other gene therapies

> “In addition, the reimbursement structure of approved gene therapies by other companies could impact the anticipated reimbursement structure of our gene therapies, if approved, and our business, financial condition, results of operations and prospects.”
> “In addition, for products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-4.1-11"></a>

### Trofinetide: United States list price and estimated net cost at launch

> “The list price of Daybue will be $21.10 per milliliter, or an estimated average net realized cost to payors of about $375,000 annually, Brendan Teehan, executive vice president, chief operating officer and head of commercial at Acadia, told Formulary Watch.”
> “There are an estimated 6,000 to 9,000 people living with Rett syndrome in the United States, according to Teehan.”

Source: [Managed Healthcare Executive (2023)](https://www.managedhealthcareexecutive.com/view/fda-approves-first-treatment-for-rett-syndrome)

<a id="topic-4.1-12"></a>

### Trofinetide: United States net product sales, 2023 to 2025

> “Net product sales of DAYBUE were $391.4 million and $348.4 million in 2025 and 2024, respectively. The increase in net product sales of DAYBUE of $43.0 million was due to the growth in DAYBUE unit sales as well as a higher average net selling price of DAYBUE in 2025 compared to 2024.”
> “Net product sales of DAYBUE were $348.4 million and $177.2 million in 2024 and 2023, respectively.”
> “Based on the number of Rett syndrome patients in the U.S., we believe there remains a substantial opportunity for new patient adoption.”

Source: [Acadia Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm)

<a id="topic-4.1-13"></a>

### Trofinetide: uptake in United States claims after approval

> “Of 8047 individuals with RTT identified, 2950 met eligibility criteria; 766 (26.0%) were treated with TROF and 2184 (74.0%) remained untreated.”
> “In this real-world analysis, only one-quarter of eligible individuals with RTT initiated TROF during the early post-approval period.”

Source: [Rashid et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13264036/)

<a id="topic-4.1-14"></a>

### Trofinetide cost-utility model submitted to Canada's Drug Agency: structure and inputs

> “The sponsor submitted a cost-utility analysis assessing the cost-effectiveness of trofinetide plus BSC compared with BSC alone for the treatment of Rett syndrome in adults and pediatric patients aged 2 years and older and weighing at least 9 kg, which aligns with the proposed reimbursement request.”
> “The analyses were conducted from both the public health care payer and societal perspectives. The time horizon in the base case was a lifetime (79.1 years), and there was a 1.5% annual discount rate for costs and effectiveness.”
> “The sponsor submitted a Markov model with 5 distinct and mutually exclusive health states. Four health states were based on the RSBQ scores: mild to moderate (0 to 25), moderate to severe (26 to 50), severe (51 to 75), and very severe (76 to 90); and dead (Figure 1 in Appendix 3).”
> “The proportion of patients who discontinued treatment in the first year was approximately 48%, and discontinuation was assumed to be approximately 10% per year for year 2 and beyond.”
> “The 12-week (1 model cycle) cost of trofinetide in the model was $84,479 to $211,797 in cycle 1 with titration, and $102,399 to $255,996 in subsequent cycles; annual cost is $455,251 to $1,113,127 (up to 40 kg), assuming zero wastage.”
> “Health care resource use costs were estimated based on published literature.8,9 It was assumed that health care resource use was the same for each treatment arm and every health state.”
> “To estimate the indirect costs (caregiver time and productivity loss), caregiving time for spinal muscular atrophy was used as a proxy based on a study conducted by Aranda-Reneo et al.11 of informal caregivers in 4 European countries (France, Germany, Spain, and the UK).”

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

<a id="topic-4.1-15"></a>

### Trofinetide cost-utility model submitted to Canada's Drug Agency: health state utilities

> “A DCE study and caregiver interviews were commissioned to develop utility-based scoring weights for the RSBQ based on the general public in Canada and the UK (N = 561).”

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

| Health state (RSBQ score) | Utility value |
| --- | --- |
| Mild to moderate (0 to 25) | “0.6409” |
| Moderate to severe (26 to 50) | “0.5386” |
| Severe (51 to 75) | “0.4158” |
| Very severe (76 to 90) | “0.2160” |

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

<a id="topic-4.1-16"></a>

### Trofinetide cost-utility model submitted to Canada's Drug Agency: results and appraisal

> “Based on the sponsor’s submitted results, trofinetide in addition to BSC is more effective (incremental quality-adjusted life-years [QALYs] = 0.578) and associated with greater total costs (incremental costs = $3,386,675) than BSC alone, resulting in an incremental cost-effectiveness ratio (ICER) of $5,864,321 per QALY gained.”
> “Trofinetide plus BSC had a 0% probability of being cost-effective at willingness-to-pay thresholds of $50,000 per QALY gained and of $100,000 per QALY gained.”
> “A price reduction of more than 98% would be required for trofinetide plus BSC to be considered cost-effective at a willingness-to-pay threshold of $100,000 per QALY gained.”
> “The trial results were extrapolated over a 79-year time horizon, and 93% of incremental QALYs estimated occurred beyond the observation period in the LAVENDER and LILAC trials.”
> “An additional scenario analysis was performed to explore the impact of discontinuation rate beyond 2 years. In this scenario, the discontinuation rate was set to 0 after year 2. This change resulted in $9,814,871 in incremental costs, and the ICER increased to $17,053,041 per QALY gained.”

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

<a id="topic-4.1-17"></a>

### Trofinetide budget impact analysis submitted to Canada's Drug Agency

> “The BIA was conducted from the perspective of the pan-Canadian drug plans over a 3-year time horizon (2025 to 2027).”
> “Under the sponsor’s base-case assumptions, 95 patients would start publicly reimbursed trofinetide in year 1, 21 in year 2, and 22 in year 3.”
> “Results of the CDA-AMC reanalyses suggest that the reimbursement of trofinetide for the treatment of Rett syndrome in patients 2 years of age and older, weighing at least 12 kg, and with a confirmed Rett syndrome diagnosis as described in Table 1 may be associated with a 3-year incremental budgetary cost of $166,461,725 (year 1: $53,775,386; year 2: $53,706,466; year 3: $58,979,873).”
> “As the size of the population with Rett syndrome as well as the uptake of trofinetide within that population remain uncertain, the estimated budget impact of trofinetide is uncertain. Scenario analyses resulted in budget impacts of up to $333 million.”
> “According to clinical expert input obtained by CDA-AMC, as well as a news release published by the sponsor,20 there are approximately 600 to 900 patients with Rett syndrome in Canada.”

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

<a id="topic-4.1-18"></a>

### Trofinetide reimbursement recommendation of Canada's Drug Agency

> “Canada’s Drug Agency (CDA-AMC) recommends that Daybue not be reimbursed by public drug plans for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older and weighing at least 9 kg.”
> “Expensive drugs for rare diseases, such as trofinetide, raise ethical considerations regarding equity, distributive justice, and the sustainability of health care budgets.”

Source: [CDA-AMC trofinetide reimbursement recommendation (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829/2636?inline=1)

<a id="topic-4.1-19"></a>

### Rett Syndrome Behaviour Questionnaire utility weights

> “This study was conducted to develop utility-based scoring weights from the 45-item Rett Syndrome Behaviour Questionnaire (RSBQ), a disease-specific measure.”
> “Participants (n=290 UK and n=271 Canada) completed the DCE survey.”
> “Disutility weights for each level of each attribute were calculated using the DCE model coefficients rescaled against the worst and best health states, which ranged from 0.22 to 0.87.”

Source: [Skrobanski et al. (2025)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2025/poster-session-5-2/the-estimation-of-utility-weights-from-the-rett-syndrome-behavior-questionnaire)

<a id="topic-4.1-20"></a>

### Systematic literature review: no published pharmacoeconomic model for Rett syndrome

> “There were 221 unique citations screened for pharmacoeconomic models, but no publications on this topic were eligible for inclusion in the SLR.”

Source: [May et al. (2024b)](https://acadia.com/en-us/pdf/healthcare-professionals/scientific-publications/congress-materials/2024_EAN_May_HTA_SLR_Pos.pdf)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
